Oncology

Angiogenesis Inhibitors in Oncology:
Implications for Health System Pharmacies

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Cardiology.

Angiogenesis Inhibitors in Oncology: Implications for Health System Pharmacies

View On-Demand Webcast

Order Audio CD-ROM

Dear Colleague,

Angiogenesis—the formation of new blood vessels—is a critical step in the growth and metastasis of solid tumors. Recently, several novel therapies have emerged that target specific molecules involved in this process. When used in combination with chemotherapy, these agents have improved response and survival in patients with a wide range of tumors, including non-small–cell lung cancer, breast cancer, metastatic colorectal cancer, and renal cell carcinoma. Two of these new agents—a vascular endothelial growth factor (VEGF) inhibitor and an epidermal growth factor receptor (EGFR) inhibitor—have received FDA approval, and several others are poised to enter the marketplace. As clinical data on these drugs accumulate, it becomes clear that angiogenesis inhibitors will be important components of many chemotherapy regimens and have a significant impact on the treatment of cancer.

We hope that you will be able to join us for Angiogenesis Inhibitors in Oncology: Implications for Health System Pharmacies, a CE on-demand webcast. Designed specifically for pharmacists by experts in the field, the symposium will focus on the mechanisms of action of these drugs, their safety and efficacy, and how best to incorporate them into treatment protocols. In light of the 2005 changes in Medicare reimbursement, we will also be discussing the requirements for reimbursement and the effects these new regulations have on planning treatment for oncology patients. We encourage you to view the webcast or order your free CD-ROM today.

Sincerely,

CHAIR
Rowena N. Schwartz, PharmD Associate Professor and Vice Chair Department of Pharmacy and Therapeutics University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania
FACULTY
Cathy Eng, MD Assistant Professor of Medicine Department of Gastrointestinal Medical Oncology University of Texas M.D. Anderson Cancer Center Houston, Texas Patrick J. Flynn, MD Principal Investigator NCI Grant Funded Metro Minnesota CCOP Clinical Assistant Professor of Medicine University of Minnesota Minnesota Oncology Hematology, P.A. Minneapolis, Minnesota	Lew M. Iacovelli, BS, PharmD Manager, Oncology Pharmacy Services Medical Oncology The Moses H. Cone Regional Cancer Center Greensboro, North Carolina

top

TARGET AUDIENCE

This satellite symposium is designed for health system and hospital pharmacists who care for cancer patients.

ACTIVITY GOAL

The goal of this activity is to provide the latest data on the use of angiogenesis inhibitors in treating metastatic colorectal cancer and other cancers, and the implications of Medicare reform for the delivery of oncology therapy in health system pharmacies.

LEARNING OBJECTIVES

Describe the key mediators of angiogenesis, and compare normal and pathologic angiogenesis.
Review VEGF overexpression in a variety of tumors.
Discuss the safety and efficacy of currently available treatments, including angiogenesis inhibitors, for metastatic colorectal cancer, breast cancer, non-small cell lung cancer, and renal cell carcinoma.
Incorporate evidence-based guidelines into appropriate treatment protocols.
Translate an understanding of the 2005 changes in Medicare reimbursement into treatment and infrastructure needs for providing therapies for oncology patients.
Interpret the coding requirements for Medicare reimbursement as part of treatment planning for oncology patients.

top

CE INFORMATION

STATEMENT OF ACCREDITATION: PHARMACISTS

Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to this program, for 2 contact hours (0.2 CEUs), is 052-000-05-003-L01.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Cathy Eng, MD, has received grant/research support from Bristol-Myers Squibb Company, Genentech, Inc, Novartis Pharmaceuticals, and Sanofi-Aventis.

Patrick J. Flynn, MD, is on the speakers bureau of Amgen, Genentech, Inc, and Sanofi-Aventis; and on the advisory board of Bristol-Myers Squibb Company, Genentech, Inc, and Sanofi-Aventis.

Lew M. Iacovelli, BS, PharmD, has received grant/research support from Amgen Inc; is a consultant for Amgen Inc, GlaxoSmithKline, Pfizer Inc, and Sanofi-Aventis; is on the speakers bureau of Amgen Inc and GlaxoSmithKline; and is on the advisory board of Pfizer Inc. and Sanofi-Aventis.

Rowena N. Schwartz, PharmD, is a consultant for, and is on the advisory boards of Genentech, Inc, and MGI Pharma; and is on the speakers bureau of Genentech, Inc, Merck & Co Inc, and MGI Pharma.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CE activity is supported by an educational grant from
Genentech, Inc.

top

1741